Zoetis Inc (ZTS) is a leading drug manufacturers-specialty and generic business based in the US. It opened the day at $200.53 after a previous close of $202.77. During the day the price has varied from a low of $197.88 to a high of $202.53. The latest price was $198.49 (25 minute delay). Zoetis is listed on the NYSE and employs 11,300 staff. All prices are listed in US Dollars.
Best for
US shares
Best for
Low-cost
Best for
Beginners
Best for
Range of stock exchanges
Since the stock market crash that started in February 2020, Zoetis's share price has had significant positive movement.
Its last market close was $198.49, which is 28.34% up on its pre-crash value of $142.23 and 120.20% up on the lowest point reached during the March 2020 crash when the shares fell as low as $90.14.
If you had bought $1,000 worth of Zoetis shares at the start of February 2020, those shares would have been worth $683.83 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,464.86.
| Open | $200.53 |
|---|---|
| High | $202.53 |
| Low | $197.88 |
| Close | $198.49 |
| Previous close | $202.77 |
| Change | $-4.28 |
| Change % | -2.1108% |
| Volume | 3,871,636 |
| 52-week range | $141.0212 - $210.1 |
|---|---|
| 50-day moving average | $204.4059 |
| 200-day moving average | $181.5524 |
| Wall St. target price | $225 |
| PE ratio | 49.7593 |
| Dividend yield | $0.9 (0.44%) |
| Earnings per share (TTM) | $3.989 |
Other fees apply. Your capital is at risk.
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | No minimum | £3.27 £728.94 total |
Capital at risk |
|
£0 | $50 | £3.63 £729.31 total |
Capital at risk |
 |
£0 | £0.01 | £1.17 £726.85 total |
Capital at risk |
 |
£0 | £50 | £3.64 £729.32 total |
Capital at risk |
|
£0 | £1 | £19.22 £744.90 total |
Capital at risk |
 |
£9.99 per month | No minimum | £18.89 £744.57 total |
Capital at risk |
 |
£0 | No minimum | £7.26 £732.94 total |
Capital at risk |
 |
£36 per year | £20 | £18.59 £744.27 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of $198.49
| 1 week (2021-09-13) | -3.18% |
|---|---|
| 1 month (2021-08-20) | -4.13% |
| 3 months (2021-06-18) | 7.07% |
| 6 months (2021-03-19) | 29.63% |
| 1 year (2020-09-18) | 23.39% |
|---|---|
| 2 years (2019-09-20) | 58.01% |
| 3 years (2018-09-20) | 120.40% |
| 5 years (2016-09-20) | 292.27% |
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Zoetis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 50x. In other words, Zoetis shares trade at around 50x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Zoetis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.9087. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zoetis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Zoetis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $3.1 billion (£2.3 billion).
The EBITDA is a measure of a Zoetis's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $7.4 billion |
|---|---|
| Operating margin TTM | 36.21% |
| Gross profit TTM | $4.6 billion |
| Return on assets TTM | 12.36% |
| Return on equity TTM | 51.94% |
| Profit margin | 25.76% |
| Book value | $9.173 |
| Market capitalisation | $94.3 billion |
TTM: trailing 12 months
There are currently 3.0 million Zoetis shares held short by investors – that's known as the "short interest". This figure is 1.2% up from 2.9 million last month.
There are a few different ways that this level of interest in shorting Zoetis shares can be evaluated.
Zoetis's "short interest ratio" (SIR) is the quantity of Zoetis shares currently shorted divided by the average quantity of Zoetis shares traded daily (recently around 1.3 million). Zoetis's SIR currently stands at 2.35. In other words for every 100,000 Zoetis shares traded daily on the market, roughly 2350 shares are currently held short.
However Zoetis's short interest can also be evaluated against the total number of Zoetis shares, or, against the total number of tradable Zoetis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zoetis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Zoetis shares in existence, roughly 10 shares are currently held short) or 0.0062% of the tradable shares (for every 100,000 tradable Zoetis shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zoetis.
Find out more about how you can short Zoetis stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zoetis.
Zoetis's total ESG risk: 28.6
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zoetis's overall score of 28.6 (as at 12/31/2018) is nothing to write home about – landing it in it in the 49th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Zoetis is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Zoetis's environmental score: 2.72/100
Zoetis's environmental score of 2.72 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Zoetis's social score: 13/100
Zoetis's social score of 13 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Zoetis is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Zoetis's governance score: 8.87/100
Zoetis's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Zoetis is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Zoetis's controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Zoetis scored a 1 out of 5 for controversy – the highest score possible, reflecting that Zoetis has managed to keep its nose clean.
Zoetis Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 28.6 |
|---|---|
| Total ESG percentile | 49.38 |
| Environmental score | 2.72 |
| Environmental score percentile | 1 |
| Social score | 13 |
| Social score percentile | 1 |
| Governance score | 8.87 |
| Governance score percentile | 1 |
| Level of controversy | 1 |
Dividend yield: 0.44% of stock value
Forward annual dividend yield: 0.49% of stock value
Dividend payout ratio: 21.3% of net profits
Zoetis has recently paid out dividends equivalent to 0.44% of its share value annually.
Zoetis has paid out, on average, around 21.3% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.49% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 0.49% return on their shares, in the form of dividend payments. In Zoetis's case, that would currently equate to about $0.9 per share.
While Zoetis's payout ratio might seem low, this can signify that the company is investing more in its future growth.
Zoetis's most recent dividend payout was on 31 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 19 July 2021 (the "ex-dividend date").
Over the last 12 months, Zoetis's shares have ranged in value from as little as $141.0212 up to $210.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zoetis's is 0.6337. This would suggest that Zoetis's shares are less volatile than average (for this exchange).
Subscribe to trending stock alerts for a chance to win
Ever wondered how to buy shares in Rocket Lab USA? We explain how and compare a range of providers that can give you access to many brands, including Rocket Lab USA.
Ever wondered how to buy shares in Camber Energy? We explain how and compare a range of providers that can give you access to many brands, including Camber Energy.
Ever wondered how to buy shares in Aterian? We explain how and compare a range of providers that can give you access to many brands, including Aterian.
Ever wondered how to buy shares in eFFECTOR Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including eFFECTOR Therapeutics.
Ever wondered how to buy shares in Santhera Pharmaceuticals Holding AG? We explain how and compare a range of providers that can give you access to many brands, including Santhera Pharmaceuticals Holding AG.
Ever wondered how to buy shares in Basilea Pharmaceutica? We explain how and compare a range of providers that can give you access to many brands, including Basilea Pharmaceutica.
Ever wondered how to buy shares in Acacia Pharma Group? We explain how and compare a range of providers that can give you access to many brands, including Acacia Pharma Group.
Ever wondered how to buy shares in Blue Water Acquisition? We explain how and compare a range of providers that can give you access to many brands, including Blue Water Acquisition.
Learn more about Aditxt’s recent performance and where you can invest in Aditxt shares. We also run through some helpful rules of thumb for any investor.
Everything we know about the OnlyFans IPO, plus information on how to buy shares.
